Ultra Hypofractionnated Radiotherapy With HDR Brachytherapy Boost.

Phase 1-2 study, comparing ultra-hypofractionnated (UH) to a moderately hypofractionnated (MH) radiation therapy, with image guided HDR prostate brachytherapy. Using iso-equivalent doses, a non-inferiority analysis will be done in order to prove UH non-inferior to MH, toxicity wise. Acceptability, tolerability, acute and late toxicity will be reported. MRI visible dominant intra-prostatic lesion will be outlines and variability between radiation oncologists and radiologists will be reported. As secondary objective, biochemical and clinical failure free survival will be reported at 5 \& 10 year

Trial Details

NCT ID
NCT05786742
Phase
NA
Sponsor
CHU de Quebec-Universite Laval
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • grade and compare reported side effects between groups
Locations (sample)
  • Québec, Canada|46.81228,-71.21454

Key Eligibility Criteria

  • Biopsy proven Prostate adenocarcinoma
  • Stage T1c, T2 (Annex 2)
  • Stage Nx or N0
  • Stage Mx or M0

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →